Tissue Repair Ltd

TRP

AU0000180887

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 12:53:18 2024-04-26 am EDT			5-day change	1st Jan Change
0.23 ^AUD	0.00%		-4.17%	+4.55%

Feb. 29	Tissue Repair Limited Announces Change of Company Secretary	CI
Feb. 28	Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Tissue Repair Ltd Appoints Michael Silberberg as Director

May 02, 2023 at 02:21 am EDT

Tissue Repair Ltd. appointed Michael Silberberg as director. Date of appointment is 26 April 2023.

Latest news about Tissue Repair Ltd

Tissue Repair Limited Announces Change of Company Secretary	Feb. 29	CI
Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Tissue Repair Secures Third US Patent for Glucoprime Compound	Dec. 18	MT
17,604,240 Options of Tissue Repair Ltd are subject to a Lock-Up Agreement Ending on 18-NOV-2023.	Nov. 17	CI
13,684,488 Ordinary Shares of Tissue Repair Ltd are subject to a Lock-Up Agreement Ending on 18-NOV-2023.	Nov. 17	CI
Tissue Repair Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Tissue Repair Limited Announces Company Secretary Changes	23-06-28	CI
Tissue Repair Secures US FDA Clearance for Phase Three Leg Ulcer Trial	23-05-29	MT
Tissue Repair Ltd Appoints Michael Silberberg as Director	23-05-02	CI
Tissue Repair Ltd Announces Board Resignations	23-04-26	CI
Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22	CI
Tissue Repair to Test TR-987 Drug in 2023	22-09-29	MT
Tissue Repair Ltd Announces Change of Company Secretary	22-09-27	CI
Tissue Repair Limited Announces That It Has Received Responses to the Matters Raised in the Type C Meeting That the Company Submitted to the FDA on June 29, 2022	22-09-27	CI
Tissue Repair Secures Second US Patent for Use of Active Ingredient in Skin Conditions	22-09-05	MT
Tissue Repair Limited to Enter a Phase 3 Program in Venous Leg Ulcers	22-09-04	CI
3,770,440 Ordinary Shares of Tissue Repair Ltd are subject to a Lock-Up Agreement Ending on 30-APR-2022.	22-04-29	CI
Australian Shares Fall Amid Global Selloff as Russia Continues Assault on Ukraine	22-03-04	MT
Tissue Repair Secures US Patent Approval for Wound Drug; Shares Sink 8%	22-03-03	MT
Tissue Repair Progresses TR-987 Towards Phase III	21-11-22	CI
Tissue Repair Ltd Appoints Tony Charara as Director	21-11-22	CI
Shares of Tissue Repair Slump 39% in Australian Bourse Debut After $16 Million IPO	21-11-18	MT
Tissue Repair Ltd has completed an IPO in the amount of AUD 22.000006 million.	21-11-16	CI
Tissue Repair Ltd has filed an IPO in the amount of AUD 22.000006 million.	21-10-07	CI

Tissue Repair Limited is an Australia-based Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987, with a secondary focus on commercializing TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. Its TR Pro+ product provides a range of benefits that assists damaged skin to heal and maintains skin hydration for a moist healing environment to encourage normal scar formation. The Company is also focused on commercializing its propriety Glucoprime active pharmaceutical ingredient (API) to treat a variety of wounds and skin conditions. Glucoprime is a Î²-glucan molecule, which is designed to assist skin healing and is delivered topically in a hydrogel formulation.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TISSUE REPAIR LTD	+4.55%	9.07M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs